News
Sanofi’s Rezurock accepted in Scotland
Sanofi has announced that eligible people in Scotland living with chronic graft-versus-host disease (cGVHD) will have access to the company’s Rezurock therapy.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Sanofi has announced that eligible people in Scotland living with chronic graft-versus-host disease (cGVHD) will have access to the company’s Rezurock therapy.